Research has demonstrated its effectiveness across tendons, ligaments, muscle, bone, and gut tissue
On July 23 and 24, the FDA's Pharmacy Compounding Advisory Committee (PCAC) met to consider whether certain peptides, including TB-500, should be added to the 503A Bulks List, which is a list of drug substances that the FDA has approved for compounding
Individuals with active cancer, recent cancer history, or strong family history of aggressive cancers should avoid BPC-157 as a precautionary measure
A few peptides suppress NK cell activity and promote regulatory T cell induction, facilitating embryo tolerance
The peptide has also shown promise in liver protection studies, demonstrating hepatoprotective effects against toxic injury and improved healing of liver damage